medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number S1

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (S1)

Oral estrogen free contraception

Celis-González C, Palacios S, Durand-Carbajal M, Antonio-Regidor P

Language: Spanish
References: 31
Page: 1-12
PDF size: 244.53 Kb.


ABSTRACT

Background: Progestogen-only pills have traditionally been associated with insufficient cycle control, strict rules for intake and with exclusive indication for women with estrogen contraindications.
Objective: To review the evolution of progestogen-only contraceptives in relation to their formulation, limitations and indications.
Method: Search PubMed bases for original articles published between 1980 and 2019 with the MeSH: Estrogen-free oral hormonal contraception; Progestogen-only contraceptives; estrogen antimineralocorticoid; Drospirenone
Results: 65 articles were found and 34 were discarded due to limitations in the methodology, limited or non-representative study populations.
Conclusions: Progestogen-only contraceptives, which contain levonorgestrel, norethisterone acetate or desogestrel, have traditionally been associated with strict schedule rules for intake and a suboptimal bleeding pattern. Drospirenone is a progestogen and estrogen-free contraceptive at a dose of 4 mg in a 24/4 regimen. The molecule has antigonadotropic, antimineralocorticoid, antiestrogenic and antiandrogenic properties. Clinical studies have demonstrated efficacy comparable to combined oral contraceptives, a zero rate of cardiovascular side effects, in particular thromboembolic events and a favorable bleeding pattern.


REFERENCES

  1. de Melo NR. Estrogen-free oral hormonal contraception: benefits of the progestin-only pill. Womens Health (Lond). 2010; 6 (5): 721-35. doi: 10.2217/whe.10.36.

  2. Rice, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 mg and levonorgestrel 30 mg daily. Hum Reprod. 1999 Apr; 14 (4): 982-5.

  3. Sarfati J, et al. Impact of combined and progestogen-only contraceptives on bone mineral density. Joint Bone Spine. 2009 Mar; 76 (2): 134-8. https://doi.org/10.1016/j. jbspin.2008.09.014

  4. Rice C, Killick S, Hickling D, Coelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrelonly preparation at three different doses. Hum Reprod 1996 Apr; 11 (4): 737-40.

  5. Healthcare Bayer. Yaz Summary of Product Characteristics; 2015.

  6. Zoely. Summary of Product Characteristics; 2011.

  7. Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018 Oct; 9 (77): 34628-38.

  8. Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul; 62 (1): 29-38. https://doi.org/10.1016/S0010- 7824(00)00133-5

  9. Rapkin AJ, et al. Drospirenone: a novel progestin. Expert Opin Pharmacother. 2007 May; 8 (7): 989-99. Review. https://doi.org/10.1517/14656566.8.7.989

  10. Richter WH, et al. Comparative biologic availability of drospirenone alone and in combination with ethinyl oestradiol after single and repeated oral administration in healthy females. (En prensa Contraception).

  11. Rohn KJ, et al. Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3’-phosphoadenosine 5’-phosphosulfate binding and structural rearrangements in regulating inhibition and activity. Drug Metab Dispos. 2012 Aug; 40 (8): 1588-95. https://doi.org/10.1124/ dmd.112.045583

  12. Duijkers IJ, et al. A randomized study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015 Jun; 20 (6): 419-27. https://doi.org/10.3109/13625 187.2015.1044082

  13. Landgren B-M, Unden a-L, Diczfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. Acta Endocrinol 1980 May; 94 (1): 89-98.

  14. Rosenberg MJ, et al. Compliance and oral contraceptives: a review. Contraception. 1995 Sep; 52 (3): 137-41. Review.

  15. Duijkers IJM, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016 Apr; 93 (4): 303-9. doi: 10.1016/j.contraception. 2015.12.007.

  16. Archer DF, et al. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015 Nov; 92 (5): 439-44. doi: 10.1016/j.contraception.2015.07.014.

  17. Palacios S, et al. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone only pill. Acta Obstet Gynecol Scand. 2019 Dec; 98 (12): 1549-57. doi: 10.1111/aogs.13688.

  18. Palacios S, Colli E, Regidor PA. A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone only pill 4 mg over 9 cycles in comparison with desogestrel 0.075 mg. (En prensa PLOS ONE).

  19. Apter D, Enrico E, Gemzell Danielsson K, Klaus Peters K. Multicenter, Open-Label Trial to Assess the Safety and Tolerability of Drospirenone 4.0 mg Over 6 Cycles in Female Adolescents, With a 7-Cycle Extension Phase. (En prensa).

  20. Regidor PA, et al. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016 Sep; 32 (9): 749-51. Epub 2016 Mar 30.

  21. Oelkers W, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995 Jun; 80 (6): 1816-21.

  22. Gaspard U, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003 Jun; 67 (6): 423-9.

  23. Hadji P, et al. Bone Health in Estrogen Free Contraception. Osteoporos Int. 2019 Dec; 30 (12): 2391-2400. Doi: 10.1007/s00198-019-05103-6.

  24. Momoeda M, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009 Dec; 35 (6): 1069-76.

  25. Doran PM, et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 2001 Nov; 16 (11): 2118-25.

  26. Römer T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstetrics 2018 Oct; 298 (4): 747-53.

  27. Bitzer J, et al. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health. 2011; 3: 127-32. doi: 10.2147/IJWH.S18735

  28. Lüdicke F, et al. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001 Jul; 76 (1): 102-7. https://doi.org/10.1016/ S0015-0282(01)01834-9

  29. Ng M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980- 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Aug 30; 384 (9945): 766-81. doi: 10.1016/S0140-6736(14)60460-8.

  30. Burkman RT, et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception. 2009 Jun; 79 (6): 424-7. doi: 10.1016/j.contraception.2008.12.013. Epub 2009 Mar 4.

  31. Exeltis USA Inc. (2019) SLYND prescribing information. U.S. FDA. Recuperado de: [https://www.accessdata.fda.gov/ drugsatfda_docs/label/2019/211367s000lbl.pdf].




2020     |     www.medigraphic.com